检索结果-南通市图书馆

Effects of salvianolic acid B on in vitro growth inhibition and apoptosis induction of retinoblastoma cells

International Journal of Ophthalmology(English edition) 2012年第3期5卷 272-276页

作者： xing-an liu department of radiotherapy, people’s hospital of zhengzhou, zhengzhou 450003. henan province, china department of radiotherapy People's Hospital of Zhengzhou Zhengzhou 450003 Henan Province China.

AIM: To observe the effects of salvianolic add B (salB) on in vitro growth inhibition and apoptosis induction of retinoblastoma HXO-RB44 cells. METHODs: The effects of salB on the HXO-RB44 cells proliferation in vitro were observed by MTT colorimetric method. The morphological changes of apoptosis before and after the treatment of salB were observed by Hoechst 33258 fluorescent staining method. Apoptosis rate and cell cycle changes of HXO-RB44 cells were detected by flow cytometer at 48 hours after treated by salB. The expression changes of Caspase-3 protein in HXO-RB44 cells were detected by Western Blot. REsULTs: salB significantly inhibited the growth of HXO-RB44 cells, while the inhibition was in a concentration-and time-dependent manner. The results of fluorescent staining method indicated that HXO-RB44 cells showed significant phenomenon of apoptosis including karyorrhexis, fragmentation and the formation of apoptotic bodies, etc. after 24, 48 and 72 hours co-culturing of salB and HXO-RB44 cells. The results of flow cytometer showed that the apoptosis rate and the proportion of cells in s phase were gradually increased at 48 hours and 72 hours after treated by different concentrations of salB. Western Blot strip showed that the expression of Caspase-3 protein in HXO-RB44 cells was gradually increased with the increase of the concentration of salB. CONCLUsION: salB can significantly affect on HXO-RB44 cells growth inhibition and apoptosis induction which may be achieved through the up-regulation of Caspase-3 expression and the induction of cell cycle arrest.

关键词： salvianolic acid B HXO-RB44 cell apoptosis Caspase-3 protein

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Targeting ferroptosis and ferritinophagy:new targets for cardiovascular diseases

引用

Journal of Zhejiang University-science B(Biomedicine & Biotechnology) 2024年第1期25卷 1-22页

作者： Yi LUAN Yang YANG Ying LUAN Hui liu Han xing Jinyan PEI Hengdao liu Bo QIN Kaidi REN Clinical systems Biology Research Laboratories Translational Medicine Centerthe First Affiliated Hospital of Zhengzhou UniversityZhengzhou450052China state Key Laboratory for Artificial Microstructures and Mesoscopic Physics School of PhysicsPeking UniversityBeijing100871China school of Laboratory Medicine Xinxiang Medical UniversityXinxiang453003China Quality Management department Henan No.3 Provincial People’s HospitalZhengzhou450052China department of Cardiology the First Affiliated Hospital of Zhengzhou UniversityZhengzhou450052China Center for Translational Medicine the First Affiliated Hospital of Zhengzhou UniversityZhengzhou450052China department of Pharmacy the First Affiliated Hospital of Zhengzhou UniversityZhengzhou450052China henan Key Laboratory of Precision Clinical Pharmacy Zhengzhou UniversityZhengzhou450052China henan Engineering Research Center for Application&Translation of Precision Clinical Pharmacy Zhengzhou UniversityZhengzhou450052China

Cardiovascular diseases(CVDs)are a leading factor driving mortality ***,an essential trace mineral,is important in numerous biological processes,and its role in CVDs has raised broad discussion for ***-mediated cell death,namely ferroptosis,has attracted much attention due to its critical role in cardiomyocyte damage and ***,ferritinophagy is the upstream mechanism that induces ferroptosis,and is closely related to *** review aims to delineate the processes and mechanisms of ferroptosis and ferritinophagy,and the regulatory pathways and molecular targets involved in ferritinophagy,and to determine their roles in ***,we discuss the possibility of targeting ferritinophagy-induced ferroptosis modulators for treating ***,this review offers some new insights into the pathology of CVDs and identifies possible therapeutic targets.

关键词： Cardiovascular disease Iron Ferroptosis Ferritinophagy Therapeutic target

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of anlotinib combined with the sTUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase Ⅱ trial

引用

Cancer Biology & Medicine 2024年第5期21卷 433-444页

作者： shuzhen Lai Peijing Li Xiaohui liu Guihong liu Tieming Xie xing Zhang Xiaoxuan Wang Jing Huang Yiqiang Tang Zhigang liu Guoping shen Chaoming Li Fangxiao Lu Lei Wang Fagui Jiang Caixing sun Yuanyuan Chen Ming Chen department of Radiation Oncology The Second Affiliated Hospital of Soochow UniversitySuzhou 215000China department of Radiation Oncology Yuebei People’s Hospital Affiliated to the Medical College of Shantou UniversityShaoguan 512026China Chinese Academy of SciencesHangzhou 310022China department of Radiation Oncology The Second Clinical Medical College of Zhejiang Chinese Medical UniversityHangzhou 311403China department of Radiation Oncology The Affiliated Hospital of Xuzhou Medical UniversityXuzhou 221004China Chinese Academy of SciencesHangzhou 310022China state Key Laboratory of Translational Medicine and Innovative Drug Development Jiangsu Simcere Diagnostics Co.LtdNanjing 210000China department of Radiation Oncology The Affiliated Huai’an First People’s Hospital of Nanjing Medical UniversityHuai’an 223399China department of Radiation Oncology Jiangxi Cancer Hospital of Nanchang UniversityNanchang 330029China department of radiotherapy Dongguan Institute of Clinical Cancer ResearchDongguan Key Laboratory of Precision Diagnosis and Treatment for TumorsAffiliated Dongguan HospitalSouthern Medical UniversityDongguan 523059China The Cancer Center The Fifth Affiliated Hospital of Sun Yat-Sen UniversityZhuhai 519000China department of Radiation Oncology The First Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou 510080China department of Oncology Maoming People’s HospitalMaoming 525000China department of Radiation Oncology Kecheng District People’s HospitalQuzhou 324003China Chinese Academy of SciencesHangzhou 310022China department of Radiation Oncology State Key Laboratory of Oncology in South ChinaSun Yat-sen University Cancer CenterGuangzhou 510060China United Laboratory of Frontier radiotherapy Technology of sun Yat-sen University&Chinese Academy of sciences Ion Medical Technology Co. LtdGuangzhou 510060China

Objective:Glioblastomas are highly vascularized malignant *** determined the efficacy and safety of the anti-angiogenic multi-kinase inhibitor,anlotinib,for a newly diagnosed ***:This multicenter,single-arm trial(NCT04119674)enrolled 33 treatment-naïve patients with histologically proven glioblastomas between March 2019 and November *** underwent treatment with the standard sTUPP regimen[fractionated focal irradiation in daily fractions of 1.8-2 Gy given 5 d/w×6 w(total=54-60 Gy)]or radiotherapy plus continuous daily temozolomide(TMZ)(75 mg/m^(2)of body surface area/d,7 d/w from the first to the last day of radiotherapy),followed by 6 cycles of adjuvant TMZ(150-200 mg/m^(2)×5 d during each 28-d cycle)plus anlotinib(8 mg/d on d 1-14 of each 3-w cycle for 2 cycles during concomitant chemoradiotherapy,8 maximal cycles as adjuvant therapy,followed by maintenance at 8 mg/*** primary endpoint was progression-free survival(PFs).secondary endpoints included overall survival(Os)and adverse events(AEs).Results:Thirty-three patients received the planned *** median PFs was 10.9 months(95%CI,9.9-18.7 months)and the 12-month PFs rate was 48.5%.The median Os was 17.4 months(95%CI,14.5-21.1 months)and the 12-month Os rate was 81.8%.The most common AEs included hypertriglyceridemia[58%(n=19)],hypoalbuminemia[46%(n=15)],and hypercholesterolemia[46%(n=15)]during concurrent chemoradiotherapy and leukopenia[73%(n=24)],hypertriglyceridemia[67%(n=22)],and neutropenia[52%(n=17)]during adjuvant *** patients discontinued treatment due to ***1(HR,5.6;95%CI,1.3-23.7;P=0.021)and RP1L1 alterations(HR,11.1;95%CI,2.2-57.2;P=0.004)were associated with a significantly shorter ***:Anlotinib plus the sTUPP regimen has promising anti-tumor activity against glioblastoma and manageable ***1 and RP1L1 alterations might be novel predictive biomarkers of the response to anlotinib.

关键词： Glioblastoma anti-angiogenesis multi-kinase inhibitor anlotinib temozolomide progression-free survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

First-line camrelizumab(a PD-1 inhibitor)plus apatinib(an VEGFR-2 inhibitor)and chemotherapy for advanced gastric cancer(sPACE):a phase 1 study

引用

signal Transduction and Targeted Therapy 2024年第4期9卷 1760-1767页

作者： Xiaofeng Chen Hao Xu Xiaobing Chen Tongpeng Xu Yitong Tian Deqiang Wang Fen Guo Kangxin Wang Guangfu Jin Xiao Li Rong Wang Fengyuan Li Yongbin Ding Jie Tang Yueyu Fang Jing Zhao Liang liu Ling Ma Lijuan Meng Zhiguo Hou Rongrong Zheng Yang liu Ni Guan Bei Zhang shuang Tong shiqing Chen xing Li Yongqian shu department of Oncology The First Affiliated Hospital with Nanjing Medical UniversityNanjingChina Gusu school Nanjing medical UniversitySuzhouChina Jiangsu Key Lab of Cancer Biomarkers Prevention and TreatmentCollaborative Innovation Center for Cancer Personalized MedicineNanjing Medical UniversityNanjingChina department of General surgery The First Affiliated Hospital with Nanjing Medical UniversityNanjingChina department of Oncology Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhouChina henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer&zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer ZhengzhouChina department of Oncology Digestive Disease Institute&Cancer Institute of Jiangsu UniversityAffiliated Hospital of Jiangsu UniversityZhenjiangChina department of Oncology Suzhou Hospital of Nanjing Medical UniversitySuzhouChina department of Oncology Nanjing PuKou People’s HospitalNanjingChina department of Epidemiology School of Public HealthNanjing Medical UniversityNanjingChina department of Pathology The First Affiliated Hospital with Nanjing Medical UniversityNanjingChina department of general surgery Jurong Branch hospital of Jiangsu Province People HospitalJurongChina department of Medical Oncology Liyang People’s HospitalLiyangChina department of radiology Nanjing PuKou People’s HospitalNanjingChina Jiangsu Hengrui Pharmaceuticals ShanghaiChina department of Medical Affairs 3D Medicines Inc.ShanghaiChina shanghai OrigiMed Co. Ltd.ShanghaiChina

Patients with advanced gastric cancer typically face a grim *** phase 1a(dose escalation)and phase 1b(dose expansion)study investigated safety and efficacy of first-line camrelizumab plus apatinib and chemotherapyfor advanced gastric or gastroesophageal junction *** primary endpoints included maximum tolerated dose(MTD)in phase 1a and objective response rate(ORR)across phase 1a and *** 1a tested three dose regimens of camrelizumab,apatinib,oxaliplatin,and *** regimen 1:camrelizumab 200 mg on day 1,apatinib 250 mg every other day,oxaliplatin 100 mg/m^(2) on day 1,and s-140 mg twice a day on days *** regimen 2:same as dose regimen 1,but oxaliplatin 130mg/*** regimen3:same as dose regimen 2,but apatinib 250 mg ***-four patients were included(9 in phase 1a,25 in phase 1b).No dose-limiting toxicities occurred so no MTD was *** 3 was set for the recommended phase 2 doses and administered in phase *** confrmed ORR was 76.5%(95%CI 58.8-89.3).The median progression-free survival was 8.4 months(95%CI 5.9-not evaluable[NE]),and the median overall survival(Os)was not mature(11.6-NE).Ten patients underwent surgery after treatment and the multidisciplinary team *** 24 patients without surgery,the median Os was 19.6 months(7.8-NE).Eighteen patients(52.9%)developed grade≥3 treatment-emergent adverse *** plus apatinib and chemotherapy showed favorable clinical outcomes and manageable safety for untreated advanced gastric cancer(ChiCTR2000034109).

关键词： regimen cancer doses

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

CT guided radioactive 125I seed implantation compared with first-line chemotherapy in treating localized advanced pulmonary carcinoma:a control study

CT guided radioactive 125I seed implantation compared with f...

引用

中国(第七届)肿瘤微创治疗学术大会暨世界影像导引下肿瘤微创治疗学会成立筹备大会

作者： Zhang Fu-Jun1,Wu Pei-Hong 1,Li Chuan-xing1,Wu Yue-Xia1,Huang Jin-Hua1, Fan Wei-Jun1,Jiao De-Chao1,liu Jian2,Li Yu-Liang3 1.department of Medical Imaging and Interventional Radiology,Cancer Center,sun Yat-sen University,Guangzhou, Guangdong,5 10060,P.R.china 2.Intervention department,henan Provincial people’s hospital,zhengzhou,henan,450003.P.R.china 3.Intervention department,The second Affiliated hospital of shandong University,Jinan,shangdong,250033,P.R.china

Objective To investigate the clinical value of CT guided radioactive seed 125I implantation(CTRIsI) in the treatment of localized advanced pulmonary *** Thirty-two patients(Group A) with localized advanced pulmonary carcinoma,received radioactive seed 125I implantation after failure in first line chemotherapy. There were 15 males,and 17 females,ageing from 31 to 73 years old,52.0 on the *** were 48 lesions in the 32 patients altogether and all the lesions had a clear border with the adjacent normal *** diameter of tumors was 4.5-7.5cm,the average was *** the cases had been confirmed as malignant by pathology(percutaneous aspiration biopsy).125I seeds of 2.2～3.3×107 megabecquerel(MBq)were implanted into these *** total number of the seeds implanted in each lesion was 10～*** dosage of the region around the tumor was *** to Treatment Planning system(TPs),we implant the 125I seeds into the tumors under CT *** picked 30 patients (Group B) to be treated by first line chemotherapy in our hospital randomly as the control *** The results of CT follow-up after two months proved that the local control rate of the group treated with 125I seeds implantation was 78.1%,one year survival rate was 65.0%,median survival time was 15 *** amount of effusion was observed in these patients during *** happened in 4 cases with one of the lungs compressed less than 30 percent and got improved healthy after conservative *** week after the procedure,bloody sputum occured in 15 *** medullary suppression and other serious complications occurred in these *** local control rate of the control group was 43.3%,one year survival rate was 48.0%,median survival time was 11 months,the incidence rate of medullary suppression is 46.3%.There was a significant difference between the two *** CTGRIsI procedure is safe and well-tolerated in treating localized advanc

关键词： Iodine radioisotopes interventional brachytherapy localized advanced stage pulmonary carcinoma evaluation studies

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

3D DsA在颅内动脉瘤介入诊疗中的应用价值

引用

实用放射学杂志 2006年第8期22卷 982-985页

作者：翟水亭李天晓宗登伟曹会存王子亮白卫星刘建文河南省人民医院介入科河南省人民医院介入科河南郑州450000

目的评价3D DsA在颅内动脉瘤诊疗中的作用,并与2D DsA比较。方法50个破裂的颅内动脉瘤均行2D DsA及3DDsA检查。观察2D DsA及3D DsA(VR)对颅内动脉瘤瘤颈和瘤体形态的显示,评估血管内栓塞治疗的可行性。获取血管内栓塞治疗的参考图像。... 详细信息

目的评价3D DsA在颅内动脉瘤诊疗中的作用,并与2D DsA比较。方法50个破裂的颅内动脉瘤均行2D DsA及3DDsA检查。观察2D DsA及3D DsA(VR)对颅内动脉瘤瘤颈和瘤体形态的显示,评估血管内栓塞治疗的可行性。获取血管内栓塞治疗的参考图像。通过对瘤颈和瘤体的测量,正确选择第1枚弹簧圈的直径及长度。结果50个破裂的颅内动脉瘤中,2D DsA能清楚显示14个动脉瘤的瘤颈;VR能清楚显示所有动脉瘤的瘤颈。2D DsA能清楚显示26个动脉瘤的形态;VR能清楚显示所有动脉瘤的形态。2D DsA认为6例不能行血管内栓塞治疗;3D DsA显示全部能行血管内栓塞治疗并栓塞成功。49个颅内动脉瘤行血管内栓塞治疗时均从3D DsA获取参考图像。48个第1枚弹簧圈选择正确。结论3D DsA在评估颅内动脉瘤血管内栓塞治疗的可行性、获得参考图像、动脉瘤精确测量等方面具有重要的临床价值。

关键词：脑颅内动脉瘤数字减影血管造影三维介入放射学

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

单倍体造血干细胞联合脐血双移植治疗儿童再生障碍性贫血的临床观察

引用

中国实验血液学杂志 2024年第3期32卷 890-895页

作者：刘焕君陈兴华张文邦郭树霞河南中医药大学附属第五临床医学院(郑州人民医院) 河南郑州450003 河南中医药大学人民医院血液科河南郑州450003

目的:探索单倍体造血干细胞移植联合脐血输注治疗儿童再生障碍性贫血的疗效及安全性。方法:纳入河南中医药大学人民医院2021年1月1日至2023年9月15日接受脐血联合单倍体造血干细胞移植治疗的9例再生障碍性贫血患儿,中位年龄为11(2-13)岁... 详细信息

目的:探索单倍体造血干细胞移植联合脐血输注治疗儿童再生障碍性贫血的疗效及安全性。方法:纳入河南中医药大学人民医院2021年1月1日至2023年9月15日接受脐血联合单倍体造血干细胞移植治疗的9例再生障碍性贫血患儿,中位年龄为11(2-13)岁,中位随访18(7.5-21)个月,回顾性分析其临床资料,对植入情况、GVHD发生率、感染等并发症及生存进行分析。结果:9例患儿全部成功植入。中性粒细胞和血小板植入中位时间分别为11.11±1.27 d、12.44±3.36 d。1例发生Ⅰ度急性消化道移植物抗宿主病,治疗后好转,后期该例患者发生浅表性胃炎及慢性消化道移植物抗宿主病,目前临床随访中。无一例患儿发生Ⅱ-Ⅳ度急性移植物抗宿主病。出血性膀胱炎3例,CMV感染5例,细菌及真菌感染5例,经对症治疗后好转。9例患儿移植后1个月内均表现为完全供者嵌合,随访两年,9名患儿全部生存,未出现复发或发生Ⅱ-Ⅳ度移植物抗宿主病,无移植相关死亡患儿。结论:单倍体造血干细胞移植联合脐血输注治疗儿童再生障碍性贫血时GVHD发生率低,程度轻,疗效显著,可以作为无HLA全相合配型患儿的一种治疗方案。

关键词：再生障碍性贫血单倍体造血干细胞移植脐血

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

系统评价芪红通络方配合推拿预防全膝关节置换术术后下肢静脉血栓的疗效

引用

辽宁中医杂志 2024年第8期51卷 73-77页

作者：王伟伟刘强熊小云李雪飞邢勇胜杨曼河南省直第三人民医院康复医学科河南郑州450000

目的系统评价芪红通络方配合推拿预防全膝关节置换术(total knee arthroplasty,TKA)术后下肢静脉血栓的疗效。方法选取2021年12月—2023年1月医院收治的96例择期行TKA术的患者为研究对象,按照随机数字表法分为对照组、观察组。术后均给... 详细信息

目的系统评价芪红通络方配合推拿预防全膝关节置换术(total knee arthroplasty,TKA)术后下肢静脉血栓的疗效。方法选取2021年12月—2023年1月医院收治的96例择期行TKA术的患者为研究对象,按照随机数字表法分为对照组、观察组。术后均给予抗感染、镇痛、营养支持等常规治疗,对照组同时给予推拿,观察组对照组基础上另给予芪红通络方,比较两组凝血功能指标[凝血酶时间(thrombin time,TT)、活化部分凝血酶时间(activated partial thrombin time,APTT)、纤维蛋白原(fibrinogen,FIB)、D-二聚体(D-dimer,D-D)]、血液流变学指标[全血高切黏度、血浆黏度、红细胞压积]、炎性因子[白细胞介素-6(interleukin-6,IL-6)、超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)]水平。随访至术后3个月,比较两组膝关节功能恢复情况,记录两组下肢静脉血栓发生情况。结果不同组间、时点间TT、APTT、FIB、D-D的主效应差异具有统计学意义(Ps-CRP、TNF-α的主效应差异具有统计学意义(Ps-CRP、TNF-α水平均降低,且观察组术后7、14 d IL-6、hs-CRP、TNF-α水平均低于对照组(P<0.05)。随访发现,观察组膝关节功能优良率(89.58%,43/48)高于对照组(70.83%,34/48),下肢静脉血栓发生率(2.08%,1/48)低于对照组(14.58%,7/48),差异均具有统计学意义(P<0.05)。结论芪红通络方配合推拿抗凝、溶栓、抗炎作用更明显,可有效预防TKA术后下肢静脉血栓形成,值得临床积极推广应用。

关键词：下肢静脉血栓全膝关节置换术推拿芪红通络方凝血功能

来源：

维普期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

食管癌调强放疗计划剂量学参数差异对放射性肺炎发生及严重程度的影响

引用

中华消化病与影像杂志（电子版） 2024年第4期14卷 320-324页

作者：段伟刘飞许光源程宇豪陈星界首市人民医院肿瘤放射治疗科安徽省236500 界首市人民医院治疗放射科安徽省236500

目的探讨食管癌调强放疗(IMRT)后剂量学参数差异对放射性肺炎(RP)发生及不同病情分级的影响。方法选取2019年6月至2023年11月界首市人民医院收治的80例食管癌患者,均实行IMRT计划,根据实施IMRT后患者是否发生RP分为发生RP组和未发生RP组... 详细信息

目的探讨食管癌调强放疗(IMRT)后剂量学参数差异对放射性肺炎(RP)发生及不同病情分级的影响。方法选取2019年6月至2023年11月界首市人民医院收治的80例食管癌患者,均实行IMRT计划,根据实施IMRT后患者是否发生RP分为发生RP组和未发生RP组,并将发生RP组根据其病情严重程度的不同进行分级。比较剂量学相关指标参数在发生RP组和未发生RP组以及不同分级RP中的差异,同时对剂量学参数数据进行Logistic多因素分析,总结剂量学相关指标的参数差异对RP发生及严重程度的影响。结果80例患者中有36例患者发生RP,44例患者未发生RP;发生RP患者中Ⅰ级20例,Ⅱ级13例,Ⅲ级3例。发生RP组的剂量学参数V10、V20、MLD均高于未发生RP组(P<0.05);3级RP患者的剂量学参数V10、V20、MLD均高于1级和2级RP患者,2级RP患者高于1级(P<0.05)。多因素分析显示:剂量学参数V10、V20以及MLD是食管癌患者应用IMRT计划后发生RP的独立危险因素。结论食管癌实行IMRT计划后发生RP及RP严重程度分级与剂量学参数差异有关;剂量学参数V10、V20、MLD是食管癌患者实行IMRT计划后发生RP的影响因素。

关键词：食管癌放射性肺炎调强放疗计划剂量学参数

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

CT-MRI同体位图像融合在高级别脑胶质瘤放射治疗靶区勾画中应用

引用

生物医学工程与临床 2024年第1期28卷 35-41页

作者：金龙杨振张鑫刘晓斌缪星宇陕西省人民医院放疗科陕西西安710068 陕西省人民医院磁共振室陕西西安710068 陕西省人民医院神经外科陕西西安710068

目的探讨同体位MRI图像(MRIsim)与CT模拟定位图像融合在高级别脑胶质瘤放射治疗靶区勾画中的临床应用价值。方法选择20例脑胶质瘤术后放射治疗患者,其中男性13例,女性7例;年龄39~69岁,平均年龄45.5岁;全部为单发病变;均已行全切或不全... 详细信息

目的探讨同体位MRI图像(MRIsim)与CT模拟定位图像融合在高级别脑胶质瘤放射治疗靶区勾画中的临床应用价值。方法选择20例脑胶质瘤术后放射治疗患者,其中男性13例,女性7例;年龄39~69岁,平均年龄45.5岁;全部为单发病变;均已行全切或不全切手术,全部经病理组织诊断证实;世界卫生组织(WHO)分级Ⅲ级6例,Ⅳ级14例。将每例患者的同体位MRIsim、常规MRI影像(MRIconv)分别与CT模拟定位图像融合。运用Dice相似指数(DsC)和豪斯多夫距离(HD)算法来评价配准的精确度。在CT与MRIsim融合图像(Fusion-CT MRIsim)、CT与MRIconv融合图像(Fusion-CT MRIconv)上分别勾画危及器官(OAR)及靶区[大体肿瘤靶区(GTV)、临床肿瘤靶区(CTV)]。评估两种融合图像(即Fusion-CT MRIsim组和Fusion-CT MRIconv组)OAR勾画体积、GTV、CTV及剂量学差异。结果融合精确度评估:除全脑外,Fusion-CT MRIsim组其余OAR DsC均高于Fusion-CT MRIconv组(Psion-CT MRIsim组OAR HD小于Fusion-CT MRIconv组(Psion-CT MRIsim组OAR勾画体积与Fusion-CT MRIconv比较,差异无统计学意义(P>0.05)。靶区:Fusion-CT MRIsim组GTV、CTV小于Fusion-CT MRIconv组[(118.2±8.0)cm^(3)vs(125.3±8.1)cm^(3)、(234.3±12.8)cm^(3)vs(256.0±13.4)cm^(3)],差异有显著统计学意义(均P=0.000)。剂量学比较:Fusion-CT MRIsim组D_(max)-PTV、D_(mean)-PTV与Fusion-CT MRIconv组[(6432.9±23.0)cGy vs(6430.4±25.2)cGy、(6159.0±13.7)cGy vs(6166.2±17.3)cGy]比较,差异无统计学意义(P>0.05)。结论CT-MRI同体位融合图像配准精确度高,可降低全脑平均剂量(D_(mean))及缩小GTV及CTV,是高级别脑胶质瘤术后精确放射治疗值得广泛应用的临床方法。

关键词： CT-MRI同体位融合高级别胶质瘤放射治疗靶区靶区勾画

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：